Filing Flows › Haemonetics (HAE) › Q4 FY26
Haemonetics (HAE) Q4 FY26 earnings results (fourth quarter fiscal 2026)
10-K filed May 20, 2026
Haemonetics (HAE) reported revenue of $346M for the fourth quarter fiscal 2026 (Q4 FY26), +5% from a year earlier and +2% from the quarter before. Operating margin was -6.6%, net loss $20.1M (5.8% of revenue).
Haemonetics, Q4 FY26: revenue $346M (+5% year over year), operating margin -6.6%, net loss $20.1M, operating cash flow $70.9M. The chart follows the revenue to costs, profit and cash.
| Q4 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $346M | +2% | +5% |
| Operating profit | −$23.0M | -134% | -132% |
| Net earnings | −$20.1M | -145% | -135% |
| Operating cash flow | $70.9M | -24% | -39% |
| Free cash flow | $53.3M | -39% | -47% |
What changed
Revenue was $346.4M in Q4 FY26, up 5% year over year and up 2% from the previous quarter. Hospital was the largest line at 46% of revenue.
Gross margin was 57.2%, down 1.2 points from Q4 FY25. Operating costs exceeded revenue by $23.0M, an operating margin of -6.6%. Operating expenses grew 82% against revenue growth of 5%. The quarter ended with a net loss of $20.1M, after a profit of $44.7M the previous quarter.
Operating cash flow was $70.9M (down 39% year over year). Non-cash charges added back $27.3M of depreciation and amortization and $9.1M of share-based compensation. Working capital and other items added $54.6M. Capital expenditures of $17.7M left free cash flow of $53.3M.
Questions
What was Haemonetics' revenue in the fourth quarter fiscal 2026?
Haemonetics (HAE) reported revenue of $346M for the fourth quarter fiscal 2026 (Q4 FY26), +5% from a year earlier and +2% from the quarter before.
Was Haemonetics profitable in the fourth quarter fiscal 2026?
Operating loss was $23.0M (-6.6% of revenue) and net loss $20.1M.
Source: Haemonetics 10-K on SEC EDGAR.